Insulin glargine: A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus

Drugs

Volumn 61, Issue 11, 2001, Pages 1599-1624

  McKeage, K ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

BODY WEIGHT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RETINOPATHY; REVIEW;

EID: 0034812965     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161110-00007     Document Type: Review

References (70)

1. Diabetes
2. Epidemiology of type II diabetes: An international perspective
3. Emerging epidemic of type 2 diabetes in youth
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes control and complications trial
7. From insulin to insulin analogs: Progress in the treatment of type 1 diabetes
8. The clinical use of insulin glargine in type 2 diabetes
9. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
10. Long acting insulin analogues: Can they provide a basal insulin level?
11. Insulin analogs with improved pharmacokinetic profiles
12. The new 'designer' insulins
13. Insulin glargine
14. Insulin analogues and their potential in the management of diabetes mellitus
15. Insulin glargine: The first clinically useful extended-acting insulin in half a century?
16. Insulin therapy in children and adolescents with type 1 diabetes
17. HOE901 - A new insulin with prolonged action
18. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
19. HOE 901, a new insulin analogue, for substitution of basal insulin requirement in type I diabetes
20. Effect of glargine on glucose disposal and lipolysis in healthy and diabetic subjects
21. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine
22. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen
23. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
24. 24h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology
25. A comparison of the pharmacodynamics (glucose lowering effect) of intravenous HOE901 and regular insulin using the euglycaemic clamp technique
26. Characterization of glucose turnover of insulin glargine in comparison with regular human insulin in healthy male subjects
27. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique
28. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
29. Insulin glargine
30. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32] insulin (HOE 901) in muscle cells
31. Effects of the long acting insulin analog insulin glargine on cultured human skeletal muscle cells; comparisons with insulin and IGF-1
32. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation
33. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B 10) and regular insulin
34. Effects of insulin glargine, human insulin and the insulin analog Asp(B 10) on the insulin receptor signaling cascade
35. Insulin analogues: Impact of cell model characteristics on results and conclusions regarding mitogenic properties
36. Insulin glargine is not carcinogenic in rats and mice
37. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects
38. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men
39. No evidence for accumulation of HOE901 after multiple injections in type I diabetic patients
40. Preclinical profile of the new long-acting insulin glargine (HOE 901)
41. Pharmacokinetics and metabolism of insulin glargine
42. Efficacy and safety of HOE 901 versus NPH insulin in patients with type I diabetes
43. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
44. Comparative clinical trial of a new long-acting insulin (HOE901) vs protamine insulin demonstrates less nocturnal hypoglycaemia
45. The effect of HOE 901 on glycemic control in type 2 diabetes
46. Standards of medical care for patients with diabetes mellitus
47. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes
48. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
49. Results of an international, multicentred, randomised 28 week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of type I diabetics
50. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
51. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type I diabetes mellitus without increasing the risk of hypoglycaemia
52. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin
53. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes
54. Results of a 12 month study: Insulin glargine (HOE 901) in combination with oral agents (pre-EASD Symp, Brussels)
55. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
56. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes
57. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes
58. Treatment with human analog (GlyA21,ArgB32,ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type I diabetes
59. Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycemic control in type 1 diabetes
60. Diabetic retinopathy in patients with type I diabetes treated with insulin glargine or NPH
61. Insulin glargine
62. 1998 Clinical practice guidelines for the management of diabetes in Canada
63. Safety of insulin glargine